Journal of Hepatology
Volume 51, Issue 6 , Pages 1021-1029 , December 2009

Early prediction of short-term development of hepatic encephalopathy in patients with acute liver disease unrelated to paracetamol. A prospective study in Japan

  • Yasuhiro Takikawa

      Affiliations

    • Department of Gastroenterology and Hepatology, Open Research Center, Advanced Medical Science Center Iwate Medical University, 19-1 Uchimaru, Morioka 020-8505, Japan
    • Corresponding Author InformationCorresponding author. Tel.: +81 19 6515111x2314; fax: +81 19 6526664.
    • ,
  • Ryujin Endo

      Affiliations

    • Department of Gastroenterology and Hepatology, Iwate Medical University, Morioka, Japan
    • ,
  • Kazuyuki Suzuki

      Affiliations

    • Department of Gastroenterology and Hepatology, Open Research Center, Advanced Medical Science Center Iwate Medical University, 19-1 Uchimaru, Morioka 020-8505, Japan
    • ,
  • Hirohito Tsubouchi

      Affiliations

    • Department of Digestive Disease and Life-style Related Disease, Kagoshima University Graduate School of Medical and Dental Sciences, Japan
    • ,
  • on behalf of the Fulminant Hepatitis Study Group of Japan

Received 10 September 2008 ,Revised 7 July 2009 ,Accepted 24 July 2009.

References 

  1. Heathcote J, Elewaut A, Fedail S, Gangl A, Hamid S, Shah M, et al. OMGE practice guideline. Management of acute viral hepatitis. World Gastroenterol News. 2004;9:1–12
  2. Dufour DR, Lott JA, Nolte FS, Gretch DR, Koff RS, Seeff RB. Diagnosis and monitoring of hepatic injury. II. Recommendations for use of laboratory tests in screening, diagnosis, and monitoring. Clin Chem. 2000;46:2050–2068
  3. Trey C, Lipworth L, Chalmers TC. Fulminant hepatic failure. Presumable contribution to halothane. N Engl J Med. 1968;279:798–801
  4. Polson J, Lee WM. AASLD position paper. The management of acute liver failure. Hepatology. 2005;41:1180–1196
  5. Rolando N, Wade J, Davalos M, Wedson J, Philpott-Howard J, William R. The systemic inflammatory response syndrome in acute liver failure. Hepatology. 2000;32:734–739
  6. Vaquero J, Polson J, Chung C, Helonowski I, Schiodt FV, Reisch J, et al. Infection and the progression of hepatic encephalopathy in acute liver failure. Gastroenterology. 2003;125:755–764
  7. Sato S, Suzuki K, Takikawa Y, Endo R, Omata M Japanese National Study Group of Fulminant Hepatitis. Clinical epidemiology of fulminant hepatitis in Japan before the substantial introduction of liver transplantation: an analysis of 1309 cases in a 15-year national survey. Hepatol Res. 2004;30:155–161
  8. Fujiwara K, Mochida S, Matsui A, Nakayama N, Nagoshi S, Toda G. Fulminant hepatitis and late onset hepatic failure in Japan. Summary of 698 patients between 1998 and 2003 analyzed by the annual national survey. Hepatol Res. 2008;38:646–657
  9. Takikawa Y, Suzuki K. Clinical epidemiology of fulminant hepatitis in Japan. Hepatol Res. 2008;38:S14–S18
  10. Keays R, Harrison PM, Wendon JA, Forbes A, Gove C, Alexander GJ, et al. Intravenous acetylcysteine in paracetamol induced fulminant hepatic failure: a prospective controlled trial. BMJ. 1991;303:1026–1029
  11. Ware A, Jones R, Shorey J, Combes B. A controlled trial of steroid therapy in massive hepatic necrosis. Am J Gastroenterol. 1974;62:130–133
  12. Rakela J. A double-blind randomized trial of hydrocortisone in acute hepatic failure. Gastroenterology. 1979;76:1279
  13. Canalese J, Gimson A, Davis C, Mellon PJ, Davis M, Williams R. Controlled trial of dexamethasone and manitol for the cerenral oedema of fulminant hepatic failure. Gut. 1982;23:625–629
  14. Rake MO, Flute PT, Shikin KB, Lewis ML, Winch J, Williams R. Early and intensive therapy of intravascular coagulation in acute liver failure. Lancet. 1971;2:1215–1218
  15. Langley PG, Hughes RD, Forbes A, Keays R, Williams R. Controlled trial of antithrombin III supplementation in fulminant hepatic failure. J Hepatol. 1993;17:326–331
  16. Takahashi Y, Shimizu M The study group of FH. Aetiology and prognosis of fulminant viral hepatitis in Japan: a multicenter study. J Gastroenterol Hepatol. 1991;6:159–164
  17. Takikawa Y, Endo R, Suzuki K, Fujiwara K, Omata M. The fulminant hepatitis study group of Japan. Prediction of hepatic encephalopathy development in patients with severe acute hepatitis. Dig Dis Sci. 2006;51:359–364
  18. Bernuau J. Acute liver failure: avoidance of deleterious cofactors and early specific medical therapy for the liver are better than late intensive care for the brain. J Hepatol. 2004;41:152–155
  19. Ostapowicz GA, Fontana RJ, Schiodt FV, Larson A, Davern TJ, Han SH. Result of prospective study of acute liver failure at 17 tertiary care centers in the United States. Ann Intern Med. 2002;137:945–954
  20. Tygstrup Ranek. Assessment of prognosis in fulminant hepatic failure. Semin Liver Dis. 1986;6:129–137
  21. O’Grady JG, Alexander GJM, Hayller KM, Williams R. Early indicators of prognosis in fulminant hepatic failure. Gastroenterology. 1989;97:439–445
  22. Robert A, Chazouilleres O. Prothrombin time in liver failure: time, ratio, activity percentage, or international normalized ratio?. Hepatology. 2007;24:1392–1394
  23. Tripodi A, Chantarangkul V, Primignani M, Fabris F, Dell’Era A, Sei C, et al. The international normalized ratio calibrated for cirrhosis (INR(liver)) normalizes prothrombin time results for model for end-stage liver disease calculation. Hepatology. 2007;46:520–527
  24. Bellest L, Eschwege V, Poupon R, Chazouilleres O, Robert A. A modified international normalized ratio as an effective way of prothrombin time standardization in hepatology. Hepatology. 2007;46:528–534

☆ The authors who have taken part in this study declared that they do not have anything to disclose regarding funding from industries or conflict of interest with respect to this manuscript.

PII: S0168-8278(09)00633-3

doi: 10.1016/j.jhep.2009.09.011

Journal of Hepatology
Volume 51, Issue 6 , Pages 1021-1029 , December 2009

Article Tools

* Image Usage & Resolution